Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy
Excerpt from the Press Release:
Carlsbad, CA, May 11, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the commencement of patient enrollment and dosing in its dose optimization study of LB1148.
J.D. Finley, interim Chief Executive Officer of Palisade Bio commented, “The dose optimization study is designed to generate valuable pharmacokinetic and pharmacodynamic data across multiple doses in healthy adult volunteers. We believe the outcome of this study will add to our growing body of data and provide the line of sight needed to further guide our LB1148 clinical development strategy moving forward.”
LB1148 is the Company’s broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. The dose optimization study is being conducted to determine if a different dosing protocol might enhance the risk profile while simultaneously providing efficacy for the development program moving forward. The study is expected to enroll approximately 32 healthy subjects.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?